121 related articles for article (PubMed ID: 27693581)
1. Fasting boosts sensitivity of human skin melanoma to cisplatin-induced cell death.
Antunes F; Corazzari M; Pereira G; Fimia GM; Piacentini M; Smaili S
Biochem Biophys Res Commun; 2017 Mar; 485(1):16-22. PubMed ID: 27693581
[TBL] [Abstract][Full Text] [Related]
2. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
Kim YK; Ahn SK; Lee M
Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
[TBL] [Abstract][Full Text] [Related]
3. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
5. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E-dependent role of autophagy in uveal melanoma.
Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
[TBL] [Abstract][Full Text] [Related]
7. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
8. In Cellulo Evaluation of the Therapeutic Potential of NHC Platinum Compounds in Metastatic Cutaneous Melanoma.
Charignon E; Bouché M; Clave-Darcissac C; Dahm G; Ichim G; Clotagatide A; Mertani HC; Telouk P; Caramel J; Diaz JJ; Bellemin-Laponnaz S; Bouvet P; Billotey C
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105692
[TBL] [Abstract][Full Text] [Related]
9. BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip¹.).
Jang GH; Lee M
Life Sci; 2014 Apr; 102(1):41-8. PubMed ID: 24625733
[TBL] [Abstract][Full Text] [Related]
10. Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.
Jang GH; Kim NY; Lee M
Mol Cell Biochem; 2015 Aug; 406(1-2):53-62. PubMed ID: 25912549
[TBL] [Abstract][Full Text] [Related]
11. Improving patient outcomes to targeted therapies in melanoma.
Eroglu Z; Smalley KS; Sondak VK
Expert Rev Anticancer Ther; 2016 Jun; 16(6):633-41. PubMed ID: 27137746
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
13. Influence of melanosome dynamics on melanoma drug sensitivity.
Chen KG; Leapman RD; Zhang G; Lai B; Valencia JC; Cardarelli CO; Vieira WD; Hearing VJ; Gottesman MM
J Natl Cancer Inst; 2009 Sep; 101(18):1259-71. PubMed ID: 19704071
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of melanoma cells selective apoptosis induced by a photoactive NADPH analogue.
Rouaud F; Boucher JL; Slama-Schwok A; Rocchi S
Oncotarget; 2016 Dec; 7(50):82804-82819. PubMed ID: 27756874
[TBL] [Abstract][Full Text] [Related]
15. Combination of ω-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study.
Ottes Vasconcelos R; Serini S; de Souza Votto AP; Santos Trindade G; Fanali C; Sgambato A; Calviello G
Melanoma Res; 2019 Jun; 29(3):270-280. PubMed ID: 30550405
[TBL] [Abstract][Full Text] [Related]
16. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
[TBL] [Abstract][Full Text] [Related]
17. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J
J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965
[TBL] [Abstract][Full Text] [Related]
18. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
20. The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.
Ponti G; Pellacani G; Tomasi A; Gelsomino F; Spallanzani A; Depenni R; Al Jalbout S; Simi L; Garagnani L; Borsari S; Conti A; Ruini C; Fontana A; Luppi G
J Clin Pathol; 2013 May; 66(5):441-5. PubMed ID: 23463675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
